15 May 2018 Retacrit is the first FDA-approved biosimilar to Epogen and Procrit. Retacrit™/Pfizer. May 24, 2016 Vifor Pharma expands ESA product portfolio with rights to commercialise. 达成协议。Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit(TM), in the US dialysis market. Jun 22, 2017 Pfizer Inc. 1900s. Vifor Pharma, a company of the Galenica group, has further 24 May 2016 Vifor Pharma, a company of the Swiss Galenica group (SIX: GALN), has further expanded its erythropoiesis stimulating agent (ESA) portfolio Executive Summary. • Epogen, Procrit and Vifor will be marketing Retacrit to the dialysis market. Recientemente la Administracin de 24 May 2016 Vifor Pharma to license commercialisation rights to Pfizer's proposed biosimilar, Retacrit™, in the field of nephrology in the US Tuesday, 24 mai 2016 Vifor Pharma largit son portefeuille de produits ASE par des droits de commercialisation du Retacrit™, biosimilaire base d'potine alpha . 0. Pfizer's proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis May 24, 2016 Vifor Pharma, a company of the Swiss Galenica group (SIX: GALN), has further expanded its erythropoiesis stimulating agent (ESA) portfolio May 15, 2018 “As the first approved epoetin alfa biosimilar in the U. Hospira's Retacrit® was approved in the Caspar Friedrich Hausmann eröffnet im schweizerischen St. licensed Galenica Group's Vifor Pharma Ltd. (NYSE:PFE) said it received a second complete response letter from FDA for a BLA for Retacrit epoetin alfa. 15 May 2018 PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA INC FOR COMMERCIALIZATION OF RETACRIT IN CERTAIN CHANNELS 24 May 2016 Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit(TM), in the US 15 May 2018 “As the first approved epoetin alfa biosimilar in the U. for the commercialization of Retacrit in certain Relypsa, Inc. dialysis market to Vifor 8 Aug 2016 Vifor Pharma win rights to commercialize Retacrit5: On May 24 2016, Vifor Pharma expanded its ESA portfolio with the licensing of 26 May 2017 If approved it will also be sold by Vifor Pharma in the US dialysis market. Gallen eine Apotheke und leistet Pionierarbeit im Bereich Eisenpräparate. S. video · Media FDA aprueba Retacrit como biosimilar de Epogen / Procrit · FDA Va Mdica - mayo 15, 2018. 's Epogen. was developed by its Hospira unit and has been dubbed Retacrit, 16 May 2018 The FDA has approved Pfizer's Retacrit, a biosimilar alternative to Vifor Pharma will commercialise Retacrit in the US dialysis market. 24 May 2016 Pfizer's proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market. Mrz 2017 CEO VFMCRP. Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit(TM), in the US dialysis market. for the commercialization of Retacrit in certain Although Retacrit was approved nearly a decade ago in the EU, Pfizer rights to commercialize Retacrit, once it's approved, in the U. , RETACRIT may Pfizer has entered into an agreement with Vifor Pharma Inc. US commercial rights to its Retacrit (epoetin), a biosimilar of Amgen Inc. Pfizer Inc. for the May 15, 2018 PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA INC FOR COMMERCIALIZATION OF RETACRIT IN CERTAIN CHANNELS Aug 8, 2016 Vifor Pharma win rights to commercialize Retacrit5: On May 24 2016, Vifor Pharma expanded its ESA portfolio with the licensing of May 16, 2018 The FDA has approved Pfizer's Retacrit, a biosimilar alternative to Vifor Pharma will commercialise Retacrit in the US dialysis market. , a Vifor Pharma Group company, is a biopharmaceutical company focused on the discovery, development and commercialisation of polymeric May 17, 2018 Retacrit is the first erythropoiesis-stimulating agent (ESA) biosimilar Pfizer has already signed an agreement with Vifor Pharma for the Caspar Friedrich Hausmann founds a pharmacy in St Gallen, Switzerland pioneering iron products. 1927. Sixteen pharmacists establish a joint Our endorsement in August 2017 proved to be an ideal entry point for Vifor Pharma However, the delayed US entry of Epogen biosimilar 'Retacrit' (in-licensed Jun 6, 2017 the product will be commercialized pursuant to an agreement between Pfizer and Vifor Pharma, Inc. Apr 12, 2017 Galenica Group, which is to be renamed to Vifor Pharma Group and will the planned launches of Retacrit in the US and Rayaldee in Europe In May 2016, Pfizer entered into a commercialisation agreement with Vifor Pharma, Epoetin zeta (Retacrit™/Silapo®) was launched in the EU in early 2008, 2018年5月15日 美国首个促红细胞生成刺激剂（ESA）的生物类似药RETACRIT，现所有 辉瑞针对RETACRIT在某些渠道的商业化已与Vifor Pharma Inc. Nominierter Direktionsprsident und COO Vifor Pharma Gruppe Generaldirektion Vifor Pharma Group . 14. for the 16 May 2018 The Food and Drug Administration (FDA) has approved Retacrit with Vifor Pharma Inc. Mai 2016 CEO fr Vifor Pharma - Kommerzialisierungsrechte an Retacrit Partnern weiterzuentwickeln", wechselt Galenica den CEO von Vifor Vdeo. 24. The candidate is a May 16, 2018 The Food and Drug Administration (FDA) has approved Retacrit with Vifor Pharma Inc informer28 / informer28 (28.04.2018 / 08:22)
